Gautam Khanna joins NATHEALTH board
NATHEALTH
Foundation has announced the appointment of Gautam Khanna to its
Board
, effective March 19, 2025.
Khanna is a General Council Member of NATHEALTH and has experience in
healthcare
operations, strategic leadership, and cross-sector partnerships.
He currently serves as CEO of P.D. Hinduja
Hospital
& Medical Research Centre. It is indicated that he has led initiatives focused on patient-centred care, operational improvement, and institutional innovation.
It is stated that he has over 35 years of experience in
hospital management
,
medical technology
, and healthcare systems.
Khanna is currently engaged in health policy and quality initiatives, including as a member of the Quality Council of India's APEX Steering Committee for Accreditation++. He also serves as President of the Association of Hospitals (Mumbai).
The foundation notes that Khanna has held several key industry positions, including Chair of the
FICCI
Health Services Committee (2022–23) and the FICCI Medical Device Forum. He has also participated in task forces for healthcare and hospital initiatives at IIT Kanpur and serves as a member of the Executive Committee for PAN IIT Alumni, India (2022–2025).
Commenting on the development, Khanna said, "I am deeply committed to supporting initiatives that foster innovation, strengthen institutional capacity, and deliver tangible impact across the healthcare value chain. Together, we have the opportunity to reimagine health systems that truly serve the needs of every Indian."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
41 minutes ago
- Mint
India boost to pharma & medtech R&D with ₹5,000 cr portal
New Delhi: The Department of Pharmaceuticals has launched an online portal for a ₹ 5,000-crore scheme it says will support innovation in pharma and medical technology. PRIP, or the Promotion of Research and Innovation in Pharma MedTech Sector, promises to make it easier to submit applications to develop novel technologies in medicine, including medical devices and drugs for communicable, non-communicable diseases and rare disease. The government is concerned about the tiny levels of domestic R&D spending, compared with many other nations, despite India being a global leader in generic drug production. While the US and China spend $60 billion and $20 billion on pharmaceutical R&D respectively, India's expenditure is only around $3 billion. PRIP aims to bridge this gap and foster a culture of research and innovation in the pharma and medtech industry. The scheme has two main components. First, strengthening research infrastructure: This involves setting up Centres of Excellence (CoEs) in the seven existing National Institutes of Pharmaceutical Education & Research (NIPERs). Second, Promoting Research in Pharma & MedTech: This component offers direct financial assistance to companies and projects for both in-house R&D and academic collaborations. It covers six priority areas, including drug discovery and development, medical devices, stem cell therapy, medicines for rare diseases and treatment for drug-resistant patients. "With the PRIP portal now live, the government is making it simple for pharma companies, medtech firms, and even startups to register and elevate their research and development capabilities," explained an official. As planned under the scheme, bigger companies can seek funding of up to ₹ 125 crore while startups can secure up to ₹ 1 crore over a period of five years, based on their milestones, the official said. India's pharmaceutical market is a global force, valued at $50 billion. While domestic consumption stands at $23.5 billion, exports contribute a significant $26.5 billion. India is the world's third-largest pharmaceutical market by volume and 14th by value of production. Over half its exports reach highly developed markets like the US, EU, and Japan, which have a high threshold on quality. Sheetal Arora, promoter and CEO of Mankind Pharma, emphasized the transformative potential of the PRIP scheme. "The new PRIP portal is a game-changer for Indian pharma. This ₹ 5,000-crore investment is exactly the boost we need as we're on the verge of massive growth. India already leads the world in generic medicines, providing 20% of the global supply. But PRIP helps us shift towards innovation, potentially bringing in another ₹ 17,000 crore for R&D by FY28. This will truly sharpen our competitive edge. The timing couldn't be better. With many major drugs losing patent protection by 2030, companies that invest in new molecules and top-tier research now will be future leaders. What's most exciting is that PRIP supports both innovation and affordable healthcare.' Arora added that PRIP supports both innovation and affordable healthcare. 'This perfectly fits India's goal of being a global innovation hub while also making medicines accessible worldwide. PRIP isn't just about money; it's about empowering Indian pharma to build a strong, self-reliant future where innovation benefits everyone,' she said.
India Today
an hour ago
- India Today
How heat stress threatens the workplace
Heat stress should not be taken lightly: Heat stress can be defined as the sum of environmental and metabolic heat loads, which increases an individual's core body temperature (CBT) that may potentially cause physiological decrements. The International Labour Organization (ILO) warns that over 70 per cent of workers globally are at risk of heat stress due to exposure to excessive heat. In addition to immediate health risks like heat fatigue, heatstroke, cardiovascular issues and electrolyte imbalances, workers may also suffer from long-term injuries that affect their health for same ILO report also says almost 26.2 million people worldwide are living with chronic kidney disease caused by heat stress at work, accounting for about three per cent of all chronic kidney disease cases. Excessive heat can also lead to mental health challenges, including anxiety, depression and mental fatigue, which can increase the likelihood of workplace ILO's latest report, Heat at Work: Implications for Safety and Health: A Global Review of the Science, Policy, and Practice, shows workplace exposure to excessive heat is particularly high in Africa (92.9%), the Arab states (83.6%), and Asia and the Pacific (74.7%). The report also says Africa and the Americas have the highest proportions of occupational injuries linked to excessive heat, with 7.2% and 6.7% of all occupational injuries, the worst in India: In India, the situation is especially dire. Most industrial workplaces regularly hit temperatures of 40C to 45C, yet there are no clear or enforceable national standards for regulating workplace heat. Unfortunately, nearly 75 per cent of the Indian workforce—around 380 million people—rely on jobs that expose them to high heat conditions. In 2024, India endured one of its most prolonged and intense summers, with temperatures soaring past 50C (122F) in several regions. 2025 continues to be the same, with the World Bank estimating that India is set to become one of the first regions where heat waves could surpass the threshold of human No labour laws exist for heat stress in India: Although heat-related regulations exist worldwide, current legislation often remains too general to address the growing risks effectively. India's labour laws currently have no specific provisions to protect workers from extreme heat. However, in recent years, many other countries have started updating their regulations and introducing new laws in response to these threats and the latest scientific the Heat at Work report outlines, the ILO's analysis of legislation from 21 countries identifies standard provisions in national occupational safety and health (OSH) responses. These include participatory risk assessments that address excessive heat, targeted strategies for high-risk workers, use of the Wet Bulb Globe Temperature (WBGT) as a heat stress indicator, hydration strategies, rest and modified schedules to limit heat exposure, cool rest areas, heat acclimatisation measures, appropriate personal protective equipment, education and awareness initiatives, and regular health need to address the situation: To begin with, prevention and control strategies for heat stress in the workplace must be strengthened to address the complexities of modern heat challenges. Excessive heat is a severe issue affecting workers, public health and the environment. Climate change and heat-related initiatives must include OSH to coordinate a response. Addressing workplace heat stress effectively will require governments, businesses, labour groups, global organisations, OSH networks and nonprofits to exchange expertise, resources and proven heat-related exposures and injuries occur not just during heat waves, so it is essential to implement preventive measures whenever heat risks are present, rather than only during extreme weather events. Affordable and practical solutions must be designed and prioritised, especially for informal work settings and micro, small and medium-sized enterprises. Thankfully, many protective measures are both cost-effective and straightforward. Ensuring proper hydration, providing rest breaks in cool, shaded spaces, adjusting work hours and implementing heat acclimatisation programmes can significantly lower risks without incurring high need participation at all levels: OSH management systems must incorporate measures to prevent and control heat stress, with workplace assessments that actively involve workers. Social dialogue should be the foundation of all actions to combat excessive heat. Engaging stakeholders at all levels, with meaningful participation from workers and their representatives, is key to creating and implementing effective heat stress policies since workers can offer invaluable insights into the daily risks they face. As the risk to worker safety from heat escalates, prioritising focused research and enhancing global understanding to drive coordinated, evidence-driven actions is to India Today Magazine- EndsTrending Reel
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Novo Nordisk launches Wegovy in India to rival Eli Lilly's weight-loss drug
Wegovy enters the Indian market as the first GLP-1 drug approved for both weight loss and cardiovascular risk reduction, competing with Eli Lilly's Mounjaro Listen to This Article Novo Nordisk has launched its once-weekly injectable weight-loss drug, Wegovy (semaglutide), in India, intensifying competition in the country's nascent but growing GLP-1 drug market. The launch pits the Danish pharmaceutical company against Eli Lilly, whose GLP-1-based therapy, Mounjaro (tirzepatide), was approved for use in India earlier this year. Both Wegovy and Mounjaro are once-weekly injectable GLP-1 receptor agonists and belong to a new class of drugs gaining global popularity for managing obesity and associated cardiovascular risks. However, they differ in indications, pricing, and clinical positioning. Novo Nordisk claims Wegovy is currently the only GLP-1-based product in India approved for both
